多配体聚糖-1在脓毒症中的研究进展  

Research progress of syndecan-1 in sepsis

作　　者：黄紫晴 江晓丽 邓莉 Huang Ziqing;Jiang Xiaoli;Deng Li(Guangdong Medical University,Zhanjiang 524002,China)

机构地区：[1]广东医科大学,广东湛江524002

出　　处：《中国急救医学》2025年第3期251-256,共6页Chinese Journal of Critical Care Medicine

基　　金：国家自然科学基金青年科学基金(31101639)。

摘　　要：脓毒症是宿主对感染反应失调或异常引发的一类疾病,可导致器官功能障碍,危及生命。近年来针对脓毒症的治疗方案在不断进步,但该病在诊断层面仍存在很大欠缺,以致错失早期治疗的良好时机。因此,寻求能够进行早期诊断和预后评估的生物标志物对于脓毒症至关重要。糖萼降解是导致脓毒症微循环功能障碍的原因之一,多配体聚糖-1(SDC-1)作为内皮糖萼层的一种组成成分,能够早期识别脓毒症、判断疾病严重程度和预测脓毒症并发症发生,并能够在患者风险分层和预后评估过程中帮助临床医生监测治疗决策的有效性,有望成为脓毒症病程进展中新的生物标志物。本研究旨在将SDC-1在脓毒症中的相关研究进展进行综述,以期能够为脓毒症的诊治提供参考。Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.Treatment options for sepsis have progressed in recent years.However,there are still significant shortcomings at the diagnostic level of the disease,resulting in missed opportunities for early treatment.The seek for biomarkers that enable early diagnosis and prognostic evaluation is critical in sepsis.Glycocalyx degradation is one of the causes of microcirculatory dysfunction in sepsis.Syndecan-1(SDC-1),one of the components of the endothelial glycocalyx layer,is effective in the early recognition of sepsis,determination of disease severity,and prediction of sepsis complications.It is expected to be a new diagnostic target for sepsis by helping to monitor the effectiveness of therapeutic decisions during risk stratification and prognostic evaluation of the patients.The purpose of this article is to summarize the progress of researches related to SDC-1 in sepsis and to provide references for the diagnosis and treatment of sepsis.

关 键 词：多配体聚糖-1 脓毒症 糖萼 生物标志物 诊断 预后评估 

分 类 号：R459.7[医药卫生—急诊医学]